Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Davis Klein
ORCID:
0009-0008-2843-1503
Observed ORCID:
0009-0008-2843-1503
OpenAlex ID:
A5111187379
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights
2024
·
Sreeja Sreekumar
, Elodie Montaudon
, et al.
·
Cancers
·
6
Abstract PO2-04-09: Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR+ Breast Cancer
2024
·
Sreeja Sreekumar
, Pierre Painsec
, et al.
·
Cancer Research
·
1
PLK1 Inhibition by Onvansertib Enhances Paclitaxel Efficacy and Overcomes Resistance in HR+/HER2− Breast Cancer Refractory to Endocrine Therapy and CDK4/6 Inhibitors
2026
·
Sreeja Sreekumar
, Migdalia E. Gonzalez
, et al.
·
Molecular Cancer Therapeutics
PDF
Abstract 329: PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models.
2026
·
Sreeja Sreekumar
, Elodie Montaudon
, et al.
·
Cancer Research
Abstract P2-07-26: Onvansertib shows synergistic efficacy in combination with paclitaxel in HR+ breast cancer: Mechanistic insights from preclinical models
2025
·
Sreeja Sreekumar
, Migdalia Gonzalez
, et al.
·
Clinical Cancer Research
Abstract PO1-04-14: PLK1 Inhibitor Onvansertib Extends the Response and Overcomes Resistance to Paclitaxel in Palbociclib-resistant HR+ Breast Cancer Patient-derived Xenografts
2024
·
Maya Ridinger
, Pierre Painsec
, et al.
·
Cancer Research
Show more works
View as search
Works count:
6
Citation count:
7
H-index:
1
I10-index:
Year
Topic
Type
